2 statistic, Student t-test, and Cochran-Cox approximation. P < .05 was considered significant.
Results: There were 77 patients treated by activation of the PERT pathway; 992 patients were included in the control group, and these patients were treated at the discretion of an attending physician without use of the algorithm from October 2013 to 2016. Both groups had similar demographics, similar distribution of risk of mortality and severity of illness, and similar average Medicare Severity Diagnosis Related Group weighting. There was no statistically significant difference in the mortality rate between the two groups. The PERT group had significantly lower intensive care unit stay and overall length of stay. No difference was seen in direct cost between the two groups. The results are summarized in the Table. There was higher utilization of interventional treatment in the PERT group (57% vs 40% for control).
Conclusions: In our institution, patients with massive or submassive PE are managed by a dedicated team that implements a clinical algorithm developed by the team. This results in expedited treatment and reduced variation of care. Intensive care unit stay and overall length of stay are reduced by this approach, and the direct cost is not increased despite the use of advanced modalities of treatment. We believe that this paradigm can be of potential value in other disease entities, particularly when multiple disciplines are involved. Methods: A retrospective review of all patients with a diagnosis of SAM was undertaken at a single institution in multiple geographic locations. Patients were identified using established criteria for the diagnosis of SAM (Table) , which excluded those diagnosed with fibromuscular dysplasia. Basic demographics, presenting symptoms, diagnostic evaluation, and outcomes were reviewed.
Results: Between 2004 and 2014, there were 116 patients diagnosed with SAM; 78 (67%) were male, with a mean age of 52.5 years (range, 23-90 years). There were 76 (65.5%) patients who presented with abdominal pain, 21 (18.1%) with flank pain, 18 (15.5%) with back pain, and 11 (9.5%) with hematuria; 16 (13.8%) patients had acute hypertension and 7 (6.0%) had hypotension. Thirteen (11.2%) patients presented with abdominal pain >30 days in duration. Twelve (10.3%) patients were asymptomatic.
Imaging revealed dissection in 96 (82.8%) patients, aneurysm in 49 (42.2%), stenosis in 24 (20.7%), occlusion/thrombosis in 18 (15.5%), pseudoaneurysm in 12 (10.3%), hemorrhage in 9 (7.8%), and arteriovenous fistula in 1 (0.9%). Disease location was renal in 57 (49.1%) patients, celiac in 51 (44.0%), superior mesenteric in 48 (41.4%), hepatic in 23 (19.8%), splenic in 18 (15.5%), inferior mesenteric in 3 (2.6%), and pancreatic in 3 (2.6%). Forty-five (38.8%) patients demonstrated evidence of end-organ ischemia.
Twenty Indications included large aneurysm in 12 patients (41.4%), end-organ ischemia in 9 (31.0%), hemorrhage in 6 (20.7%), and chronic pain in 2 (6.7%). There was one perioperative death. Presence of dissection was associated with successful medical management (P ¼ .0007). Statistically significant variables associated with need for intervention included pseudoaneurysm (P ¼ .002) and hemorrhage (P ¼ .0003).
There were 109 (94%) patients who underwent serial imaging, with mean follow-up of 37.2 months (range, 0-197.2 months). Nine (8.3%) patients had progression of radiologic findings and 17 (15.6%) had new findings seen in a different artery. Presentation of patients with acute abdominal pain was the only statistically significant variable associated with new findings on subsequent imaging (P ¼ .03).
Conclusions: SAM remains an uncommon yet important disease process that may require intervention. Therefore, it is important that the vascular surgery community be aware of this disease. Patients with SAM presenting with dissection are more likely to avoid invasive intervention. Those presenting with pseudoaneurysm and hemorrhage are more likely to fail to respond to medical management, and intervention should be considered. Serial imaging is imperative to identify disease progression, especially in those patients who present with acute abdominal pain.
Author Disclosures: K. X. Peng: Nothing to disclose; V. J. Davila: Nothing to disclose; W. M. Stone: Nothing to disclose; F. E. Shamoun: Nothing to disclose; S. G. Naidu: Nothing to disclose; R. D. McBane: Nothing to disclose; S. R. Money: Nothing to disclose. Background: Acute mesenteric ischemia (AMI) is a challenging clinical problem associated with significant morbidity and mortality. Despite increasing adoption of endovascular strategies to manage AMI, few contemporary reports focus on patients undergoing open mesenteric bypass (OMB). This is notable because there is a subset of patients who are poor candidates for peripheral intervention, including those with flush aortic visceral vessel occlusion, long-segment occlusive disease, and thrombosed mesenteric stents or bypass. Historical reports identify a retrograde OMB configuration as the safest choice because of the perception that an antegrade approach has higher risk. The purpose of this analysis was to review our experience with OMB and to compare outcomes of antegrade and retrograde OMB in the treatment of AMI.
Outcomes of Antegrade and
Methods: A single-center, retrospective chart review was performed to identify all patients who underwent OMB for AMI from 2002 to 2016. Preoperative history of mesenteric revascularization, demographics, comorbidities, operative details, and outcomes were abstracted. The primary end point was in-hospital mortality. Secondary end points included complications, reintervention, and overall survival. Kaplan-Meier methodology was used to characterize reintervention and survival. Results: Eighty-two patients (female, 54%; age, 63 6 12 years) underwent aortomesenteric bypass (aortoceliac/superior mesenteric, n ¼ 44; aortomesenteric, n ¼ 38) for AMI. History of prior stent or bypass was present in 20% (n ¼ 16). A majority (76%; n ¼ 62) underwent antegrade bypass; the remainder received retrograde infrarenal aortoiliac inflow. Patients receiving antegrade OMB were significantly more likely to be male (53% vs 25%; P ¼ .03) and to have coronary artery disease (48% vs 25%; P ¼ .05), chronic obstructive pulmonary disease (52% vs 25%; P ¼ .03), and peripheral arterial disease (60% vs 35%; P ¼ .05). Additional details regarding comorbidities, procedure-related variables, and outcomes are highlighted in the Table. For all subjects, concurrent bowel resection occurred in 45% (n ¼ 37; antegrade vs retrograde, P ¼ .9), whereas 37% (n ¼ 30) underwent subsequent resection during second-look operations. In-hospital mortality was 34% (n ¼ 28; 30-day mortality, 26%; multiple organ dysfunction, 20; bowel infarction, 4; hemorrhage/anemia, 2; arrhythmia; 1, stroke, 1), median length of stay was 16 (interquartile range, 9-35) days, and 76% (n ¼ 64) experienced at least one major complication with no difference between antegrade and retrograde configurations. At mean follow-up of 18 6 29 (median, 4; interquartile range, 1-26) months, 10 (12%) subjects experienced aortomesenteric bypass reintervention (bypass thrombosis + redo bypass, 4; percutaneous transluminal angioplasty, 3; mycotic pseudoaneurysm + redo mesenteric bypass, 2; femoral vein conduit anastomotic aneurysm, 1; primary patency: 82% 6 6% at 1 year, 82% 6 6% at 3 years [95% confidence interval, 0.7-0.9]). Overall survival at 1 year and 5 years was 57% 6 5% and 50% 6 6%, respectively (Fig) . Bypass configuration was not associated with significant differences in complications or survival; however, retrograde bypass had higher risk of reintervention (hazard ratio, 3.7; 95% confidence interval, 1-14; P ¼ .05).
Conclusions: OMB for AMI results in significant morbidity and mortality, irrespective of bypass configuration. Antegrade OMB is associated with outcomes comparable to those of retrograde OMB. The bypass configuration choice should be predicated on the patient's presentation, the anatomy, and the surgeon's preference; however, an antegrade configuration may provide lower risk of reintervention.
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